Riverbridge Partners LLC cut its position in shares of Chemed Co. (NYSE:CHE) by 4.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 469,710 shares of the company’s stock after selling 19,787 shares during the period. Chemed accounts for about 2.8% of Riverbridge Partners LLC’s investment portfolio, making the stock its 5th largest position. Riverbridge Partners LLC owned approximately 2.93% of Chemed worth $133,059,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Chemed by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,861,197 shares of the company’s stock worth $594,801,000 after purchasing an additional 35,966 shares in the last quarter. Vanguard Group Inc raised its stake in shares of Chemed by 2.0% during the 3rd quarter. Vanguard Group Inc now owns 1,861,197 shares of the company’s stock worth $594,801,000 after purchasing an additional 35,966 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Chemed by 1.5% during the 3rd quarter. Acadian Asset Management LLC now owns 576,079 shares of the company’s stock worth $184,100,000 after purchasing an additional 8,586 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Chemed by 69.5% during the 3rd quarter. Renaissance Technologies LLC now owns 233,690 shares of the company’s stock worth $74,683,000 after purchasing an additional 95,790 shares in the last quarter. Finally, MERIAN GLOBAL INVESTORS UK Ltd raised its stake in shares of Chemed by 24.8% during the 3rd quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 180,144 shares of the company’s stock worth $57,570,000 after purchasing an additional 35,841 shares in the last quarter. 87.73% of the stock is owned by institutional investors.
In other news, insider Nicholas Michael Westfall sold 5,709 shares of Chemed stock in a transaction that occurred on Tuesday, December 11th. The stock was sold at an average price of $301.75, for a total transaction of $1,722,690.75. Following the sale, the insider now owns 16,052 shares of the company’s stock, valued at approximately $4,843,691. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Spencer S. Lee sold 669 shares of Chemed stock in a transaction that occurred on Friday, November 30th. The stock was sold at an average price of $314.76, for a total value of $210,574.44. Following the sale, the insider now directly owns 30,589 shares in the company, valued at approximately $9,628,193.64. The disclosure for this sale can be found here. Insiders sold a total of 30,662 shares of company stock worth $9,401,153 in the last ninety days. Insiders own 4.82% of the company’s stock.
A number of research analysts have recently commented on the company. Zacks Investment Research lowered Chemed from a “buy” rating to a “hold” rating in a report on Tuesday, September 25th. Bank of America assumed coverage on Chemed in a report on Friday, October 12th. They set a “buy” rating and a $390.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $324.00.
Shares of NYSE CHE traded down $0.40 during mid-day trading on Monday, reaching $277.61. 4,515 shares of the company traded hands, compared to its average volume of 114,940. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.11 and a current ratio of 1.14. The firm has a market cap of $4.50 billion, a price-to-earnings ratio of 51.66, a P/E/G ratio of 1.60 and a beta of 1.23. Chemed Co. has a fifty-two week low of $243.95 and a fifty-two week high of $335.99.
Chemed (NYSE:CHE) last released its earnings results on Monday, October 29th. The company reported $3.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.80 by $0.27. The firm had revenue of $444.15 million for the quarter, compared to analyst estimates of $445.16 million. Chemed had a return on equity of 35.13% and a net margin of 11.73%. The company’s revenue was up 6.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.15 EPS. As a group, equities research analysts forecast that Chemed Co. will post 11.41 earnings per share for the current year.
WARNING: This article was originally posted by Zolmax and is the sole property of of Zolmax. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://zolmax.com/investing/riverbridge-partners-llc-cuts-stake-in-chemed-co-che/2824381.html.
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Featured Story: Capital gains and your 401(k) or IRA
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.